{"code":"C62756","name":"Tertomotide","terminology":"ncit","version":"26.09d","conceptStatus":"DEFAULT","leaf":true,"active":true,"synonyms":[{"name":"TERTOMOTIDE","termType":"PT","type":"FULL_SYN","typeCode":"P90","source":"FDA","code":"55R7RG342O","subSource":"UNII"},{"name":"GV 1001","termType":"CN","type":"FULL_SYN","typeCode":"P90","source":"NCI"},{"name":"GV-1001","termType":"CN","type":"FULL_SYN","typeCode":"P90","source":"NCI"},{"name":"GV1001","termType":"CN","type":"FULL_SYN","typeCode":"P90","source":"NCI"},{"name":"Human Telomerase Reverse Transcriptase (EC 2.7.7.49)-(611-626)-Peptide (Telomerase Catalytic Subunit Fragment)","termType":"SN","type":"FULL_SYN","typeCode":"P90","source":"NCI"},{"name":"PrimoVax","termType":"FB","type":"FULL_SYN","typeCode":"P90","source":"NCI"},{"name":"Tertomotide","termType":"PT","type":"FULL_SYN","typeCode":"P90","source":"NCI"},{"name":"Tertomotide","type":"Preferred_Name","typeCode":"P108"}],"definitions":[{"definition":"A synthetic peptide vaccine, containing 16 amino acid residues (611-626) of the human telomerase reverse transcriptase catalytic subunit (hTERT), with potential antineoplastic activity. Telomerase, a reverse transcriptase normally repressed in healthy cells, is overexpressed in most cancer cells and plays a key role in cellular proliferation. Vaccination with tertomotide may activate the immune system to mount a cytotoxic T-lymphocyte (CTL) response against telomerase-expressing cells.","code":"P97","type":"DEFINITION","source":"NCI"}],"properties":[{"code":"P210","type":"CAS_Registry","value":"915019-08-8"},{"code":"P322","type":"Contributing_Source","value":"FDA"},{"code":"P322","type":"Contributing_Source","value":"GDC"},{"code":"P319","type":"FDA_UNII_Code","value":"55R7RG342O"},{"code":"P366","type":"Legacy Concept Name","value":"GV1001"},{"code":"P375","type":"Maps_To","value":"Tertomotide"},{"code":"P399","type":"NCI_Drug_Dictionary_ID","value":"502114"},{"code":"P330","type":"PDQ_Closed_Trial_Search_ID","value":"502114"},{"code":"P329","type":"PDQ_Open_Trial_Search_ID","value":"502114"},{"code":"P106","type":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"code":"P106","type":"Semantic_Type","value":"Pharmacologic Substance"},{"code":"P207","type":"UMLS_CUI","value":"C1831942"}],"parents":[{"code":"C1663","name":"Antineoplastic Vaccine"},{"code":"C1752","name":"Peptide Vaccine"}],"associations":[{"code":"A8","type":"Concept_In_Subset","relatedCode":"C63923","relatedName":"FDA Established Names and Unique Ingredient Identifier Codes Terminology"},{"code":"A8","type":"Concept_In_Subset","relatedCode":"C157711","relatedName":"GDC Terminology"},{"code":"A8","type":"Concept_In_Subset","relatedCode":"C157712","relatedName":"GDC Therapeutic Agent Terminology"},{"code":"A8","type":"Concept_In_Subset","relatedCode":"C177537","relatedName":"GDC Value Terminology"},{"code":"A8","type":"Concept_In_Subset","relatedCode":"C176424","relatedName":"NCI Drug Dictionary Terminology"},{"code":"A8","type":"Concept_In_Subset","relatedCode":"C128784","relatedName":"NCIt Antineoplastic Agent Terminology"},{"code":"A32","type":"Is_Value_For_GDC_Property","relatedCode":"C1909","relatedName":"Pharmacologic Substance"}],"inverseAssociations":[{"code":"A31","type":"Has_GDC_Value","relatedCode":"C1909","relatedName":"Pharmacologic Substance"}],"roles":[{"code":"R124","type":"Chemical_Or_Drug_Has_Mechanism_Of_Action","relatedCode":"C45548","relatedName":"Antigen Sensitization"},{"code":"R72","type":"Chemical_Or_Drug_Affects_Cell_Type_Or_Tissue","relatedCode":"C12543","relatedName":"Cytotoxic T-Lymphocyte"},{"code":"R125","type":"Chemical_Or_Drug_Has_Physiologic_Effect","relatedCode":"C40912","relatedName":"Immunopotentiation"},{"code":"R125","type":"Chemical_Or_Drug_Has_Physiologic_Effect","relatedCode":"C19053","relatedName":"T-Cell Activation"}],"history":[{"code":"C62756","action":"create","date":"2006-10-27"},{"code":"C62756","action":"modify","date":"2007-09-27"},{"code":"C62756","action":"modify","date":"2009-04-06"},{"code":"C62756","action":"modify","date":"2009-08-03"},{"code":"C62756","action":"modify","date":"2009-11-23"},{"code":"C62756","action":"modify","date":"2014-02-03"},{"code":"C62756","action":"modify","date":"2016-08-29"},{"code":"C62756","action":"modify","date":"2017-03-20"},{"code":"C62756","action":"modify","date":"2017-11-27"},{"code":"C62756","action":"modify","date":"2018-04-30"},{"code":"C62756","action":"modify","date":"2019-02-25"},{"code":"C62756","action":"modify","date":"2020-12-28"},{"code":"C62756","action":"modify","date":"2021-04-26"},{"code":"C62756","action":"modify","date":"2021-05-24"},{"code":"C62756","action":"modify","date":"2022-01-31"},{"code":"C62756","action":"modify","date":"2023-07-31"},{"code":"C62756","action":"modify","date":"2026-02-23"},{"code":"C62756","action":"modify","date":"2026-09-28"}],"maps":[{"type":"Has Synonym","targetName":"Tertomotide","targetTermType":"PT","targetCode":"therapeutic_agents","targetTerminology":"GDC"}]}